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Abstract 
 
[Purpose] 
 Receptor tyrosine kinases (RTKs) such as epidermal growth factor receptor (EGFR) and 
hepatocyte growth factor receptor (MET) are the best-known targets of therapy for non-small 
cell lung cancer (NSCLC). Previously, our laboratory has revealed that stratifin (SFN, 14-3-3 
sigma) acts as a novel oncogene, accelerating tumor initiation and progression of lung 
adenocarcinoma and interacts with ubiquitin-specific protease 8 (USP8). In this study, I 
investigated whether stratifin (14-3-3 σ or SFN) enhances RTK stabilization through abnormal 
USP8 activation in lung adenocarcinoma. 
 
 [Materials and Methods] 
 Expressions of USP8 and SFN in human lung adenocarcinoma tissues (n=193) were 
examined by immunohistochemistry and statistically analyzed with clinicopathological features 
of patients. Functional analysis of USP8 and SFN such as cellular proliferation assay, apoptosis 
assay, and wound healing assay was examined after siRNA-USP8 or SFN transfection. 
Regulation mechanism of USP8 and SFN on RTKs stabilization was demonstrated using co-
immunoprecipitation, western blot analysis, and immunofluorescence analysis. 
 
[Results] 
 USP8 specifically bound to SFN in lung adenocarcinoma cells. Both USP8 and SFN 
showed higher expression in human lung adenocarcinoma than in normal lung tissue, and USP8 
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expression was significantly correlated with SFN expression. Expression of SFN, but not that of 
USP8, was associated with histological subtype, pathological stage, and prognosis. In vitro, 
USP8 binds SFN at the early- and late-endosome in immortalized adenocarcinoma in situ (AIS) 
cells. Moreover, USP8 or SFN knockdown led to down-regulation of tumor cell proliferation, 
RTK expression, and expression of downstream factors including AKT and STAT3, as well as 
accumulation of ubiquitinated RTKs for lysosomal degradation. Additionally, transfection with 
mutant USP8 and mutant SFN, which are unable to interact each other, reduced the expression of 
RTKs and their downstream factors. 
 
[Discussion] 
 RTKs are regulated by ubiquitin-lysosome system, and aberrant stabilization of RTKs 
contributes to the proliferative activity of many human cancers, including NSCLC.  Base on the 
IHC results, the biological effect of USP8 might be included in that of the multi-function 
proteins, SFN and the expression of USP8 itself may not influence the final outcome. From the 
facts that phospho-USP8 binds to SFN and knockdown of SFN reduces the levels of USP8 
protein, abnormal overexpression of SFN in lung adenocarcinoma might promote interaction 
with USP8 and induce a conformational change of USP8 that may result in an acceleration of its 
enzymatic activity and stability. Therefore, a SFN inhibitor would be a more selective and 
desirable therapeutic target for lung adenocarcinoma than USP8. 
 
[Conclusion] 
  In this study, I demonstrate SFN induces aberrant activation of USP8 and subsequently 
protects RTKs from lysosomal degradation, resulting in hyperactivation of these signaling 
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pathways. SFN may be central to the development of a useful therapeutic strategy for both early 
and advanced lung adenocarcinomas. 
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1. Introduction  
1-1 Current treatment of lung adenocarcinoma 
 The rate of mortality due to lung cancer increased rapidly in the 20th century for both 
men and women worldwide (1). The most common histological type of lung cancer is 
adenocarcinoma, categorized as non-small cell lung cancer (NSCLC), which has a 5-year 
survival rate of approximately 40%. However, Noguchi et al. have demonstrated that 
adenocarcinoma in situ (AIS, type A and B in the Noguchi classification) has an extremely 
favorable outcome, with a 5-year survival rate of 100% (2). AIS shows stepwise progression to 
early but invasive adenocarcinoma (eIA, type C in the Noguchi classification), which has a 
relatively poorer outcome (Fig.1) (3).  
 According to extensive molecular analyses, lung adenocarcinoma cells is well-known to 
harbor various genetic alterations which induce many events including up-regulation of 
oncogenes, down-regulation of tumor suppressor genes, and resistance to apoptotic cell death, 
thus facilitating tumor progression. The frequencies of some genetic alterations significantly 
differ among populations. In the case of Japan patient’s population, mutation of receptor tyrosine 
kinases (RTKs) including epidermal growth factor receptor (EGFR), human epidermal receptor 2 
(HER2), and hepatocyte growth factor receptor (MET) are the most common driver mutation 
(Fig.2) (4).  
 Within recent several years, diverse new-targeted therapies including EGFR-targeting 
drug such as gefitinib and erlotinib, anaplastic lymphoma kinase (ALK)/proto-oncogene1 
(ROS1)-targeting drug such crizotinib have approved for advanced stage of lung 
adenocarcinoma. Despite these treatments provide remarkable effect for patients who are 
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harboring specific genetic alteration, the most drugs lead acquired drug resistance, induction of 
second mutation, and high toxicity against wild-type form.  
Unlike the current treatment strategy for advanced adenocarcinomas, no therapeutic 
approach for early-stage lung adenocarcinomas such as adenocarcinoma in situ (AIS) has yet 
been established, except surgical resection. Moreover, the number of genetic alteration such as 
EGFR, K-RAS, and p16 inactivation is limited in early-stage lung adenocarcinoma (Fig.1). Thus, 
discovering biomarker for early-stage of lung carcinoma is essential for early diagnosis and 
targeting therapy. 
 
1-2 The characteristic of stratifin (SFN) in lung 
adenocarcinoma 
 Stratifin (SFN, 14-3-3 sigma) is the most distinct member of the highly conserved 14-3-3 
protein family (5), which includes the beta, epsilon, eta, gamma, tau, zeta, and sigma isoforms 
(Fig. 3A) (6). All 14-3-3 proteins can form both homo- and hetero-dimers, except that SFN 
prefers homo-dimers, and bind to a specific phospho-serine/threonine-containing motif on 
various proteins (Fig. 3B) (7). 14-3-3 proteins are ubiquitously expressed in human tissue. 
Although each of the 14-3-3 isoforms has unique tissue-specific functions, SFN is the form most 
directly related to tumor initiation and progression in the early lung adenocarcinoma (7, 8). 
Physiological SFN acts as an adaptor protein that controls signal transduction, protein trafficking, 
the cell cycle, and apoptosis (9). However, modification of SFN expression occurs in many 
human cancers including lung, skin, breast, endometrium, head and neck, liver, and prostates. 
Aberrant expression of SFN in various cancers is caused by different CpG methylation status. 
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For example, unlike hypermethylation of SFN in breast cancer (10), hypomethylation in SFN 
promoter participates in the overexpression of SFN to accelerate lung tumor progression (11). 
Nevertheless, lung tissue specific molecular network of SFN to contribute tumor progression has 
been unknown.  
 Previously, our group attempted to screen factors that bound specifically to SFN. In 
order to identify SFN binding partners in lung adenocarcinoma cells, A549 cells were transfected 
with SFN vectors and subjected to pull-down assay and LC-MS/MS analysis. Among the 
candidate proteins, I focused on USP8 as a direct binding partner of SFN in this study.  
 
1-3 The characteristic of ubiquitin-specific protease 8 (USP8) 
in lung adenocarcinoma 
  USP8 is a ubiquitin-specific protease (USP), being one of the deubiquitinating enzymes 
(DUBs) that stabilize specific protein substrates by removing ubiquitin from them (12).  USP8 
contains microtubule interacting and transport domain (MIT domain, residues 8-137), rhodanese-
like domain (Rho domain, residue 185-310), two Src homology 3(SH3)-binding domains (SH3 
domains, residues 405-413 and 700-708), 14-3-3 binding motif (residues 715-720), and 
deubiquitinase catalytic domain (DUB domain, residues 774-1106) with the conserved boxes 
surrounding the catalytic cysteine (residues 778-793) and histidine (residues 1051-1068) (Fig. 4) 
(13).  
 USP8 has already been reported to target several particular substrates, including G-
protein-coupled receptors (smoothened and frizzed) (14, 15), neuregulin receptor degradation 
protein-1 (Nrdp1) (16), and RTKs (17-19), which are involved in a number of human diseases 
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including malignant neoplasms. However, the mechanisms responsible for controlling the 
deubiquitination activity of USP8 and mutation or expression level of USP8 in lung 
adenocarcinoma are still poorly understood. Among the various targets of USP8, RTKs such as 
EGFR and MET are the best-known therapeutic targets in lung cancer (20). Moreover, USP8 has 
been reported to be a novel therapeutic target for tyrosine kinase inhibitor (TKI)-resistant and -
sensitive NSCLS, as USP8 inhibition induces degradation of RTKs (21). Even though inhibition 
of USP8 is beneficial for overcoming TKI resistance, it can be easily envisaged that this might 
have various side effects in view of its influence on the normal physiological function of USP8. 
Supportively, USP8 was first demonstrated as a growth-regulated ubiquitin isopeptidase (22), 
deletion of which caused embryonic lethality in mice (23), implying that the normal 
physiological function of USP8 is crucial for cell survival.  
 
1-4 The regulation mechanism of receptor tyrosine kinases 
(RTKs) in lung adenocarcinoma  
1-4-1 The role of RTKs in lung adenocarcinoma  
 In normal cells, ligand-mediated RTKs activation such as EGFR and MET is strictly 
controlled (Fig. 5). Activated RTKs undergo rapid endocytosis and subsequent degradation in 
lysosomes within a couple of hours (24). This process contributes to down-regulation of 
downstream signaling by which activation of RTKs is cancelled, resulting in abolition of over-
proliferation (25). Meanwhile, activated RTKs lead to multiple downstream signaling events 
such as AKT, ERK, and STAT3 pathways that control various processes including cellular 
proliferation, cell survival, differentiation, invasion, angiogenesis, and cell migration (26). 
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Overexpression of RTKs typically correlates with poor prognosis reflected in the unfavorable 
progression free survival and overall survival. Active somatic mutations of RTKs are found 
particularly in NSCLC patients. The most prominent mutations in EGFR are found in exon 18-21 
in tyrosine kinase domain in which patients harboring the mutations have sensitivity for TKIs 
treatment such as gifitinib and erlotinib as first generation, afitinib as second generation, and 
osimetinib as third generation (27).  In addition to EGFR mutation, MET gene alterations such as 
exon 14 internal deletions, point mutations, and gene amplification are oncogenic in NSCLC 
(28). Favorable responses of anti-MET TKIs such as cabozantinib in MET-mutated NSCLC have 
been reported. Although these treatments initially have a fast antitumor effect, these patients 
acquire drug resistance against TKI after a median of 10-16 months for drug administration (26, 
29). This phenomenon is thought to be a result of crosstalk among RTKs to escape from therapy. 
Thus, novel biomarker that can control various RTKs simultaneously is desired to improve 
patient survival. 
  
1-4-2 Ubiquitination and deubiquitination system of RTKs  
 Ubiquitination is a post-translational modification mediated by the ubiquitin conjugating 
system which is composed of E1, E2, and E3 enzymes (30). Ubiquitin addition may take the 
form of single molecule attachment to one or multiple lysines (mono-ubiquitination) or multiple 
chain attachment (poly-ubiquitination) with each subsequent ubiquitin attached to a lysine of the 
prior. Several lysine residues in ubiquitin protein are utilized for chain formation including 
Lysine 6, (K6), K11, K29, K48, and K63 (31).  
 Ubiquitination is a reversible modification, as conjugated ubiquitin molecules can be 
cleaved from target proteins by DUBs. This process is referred to as deubiquitination, recycling 
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target proteins to enhance their stabilization. These reactions have an important role to determine 
fate of target proteins.  
 For example, Cbl is a E3 ubiquitin ligase responsible for K63-linkage medicated 
ubiquitination of activated RTKs and interacts with phosphotyrosine 1045 and 1003 of EGFR 
and MET, respectively (32).  The activated RTKs with polyubiquitin undergo endocytosis and 
are sorted into either lysosomal degradation or recycling back to the plasma membrane by 
endosomal DUBs such as USP8 (33). USP8 functions at two stages of plasma membrane 
receptor trafficking; at early endosomes or late endosomes.  
 In this study, I focus on SFN and USP8 function at early endosomes, which cleaves 
poly-ubiquitin of RTKs to recycle them back to plasma membrane for abnormal distribution of 
RTKs with downstream signal transduction.  
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2. Materials and methods  
2-1 Patients and sample selection  
The specimens of lung adenocarcinomas (n=193) were selected that had been surgically 
resected at the University of Tsukuba Hospital (Ibaraki, Japan) between 1999 and 2007. Follow-
up information for all of the corresponding patients was obtainable from the medical records. 
Informed consent for use of their materials had been obtained from all of the patients. The	study	was	 approved	by	 the	 Institutional	Ethics	Review	Committee	 and	 the lung adenocarcinoma 
cases were classified according to the UICC TNM classification of malignant tumors (seventh 
edition) and the World Health Organization (WHO) classification of malignant tumors (fourth 
edition) (34, 35) 
 
2-2 Immunohistochemistry (IHC) 
 Four-µm-thick tissue sections were used from formalin-fixed paraffin-embedded (FFPE) 
tissue microarray (TMA) blocks. Each TMA block comprised 24 specimens containing lung 
adenocarcinoma tissue in a 48-core slide. The sections were deparaffinized and rehydrated, 
followed by blocking of endogenous peroxidase using 3% H2O2 for 30 min at room temperature. 
Subsequently, antigen retrieval was performed using an autoclave with 10 mM Tris-EDTA 
buffer (pH 9.0) at 105°C for 10 min. Immunostaining was performed using a Dako Autostainer 
Link 48 (Agilent Technologies, Santa Clara, CA) with the appropriate primary antibodies and 
REAL envision HRP rabbit/mouse (Agilent Technologies) as a secondary antibody. The 
immunoreactivity was detected with DAB (Dako REAL Envision Detection System; Agilent 
Technologies), and counterstaining was performed with hematoxylin for 1 min. The evaluation 
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of USP8 and SFN was according to the intensity of cytoplasmic staining. The staining was 
judged to be positive when the cytoplasm of the tumor cells was stained more strongly than that 
of the alveolar epithelium. Testis tissue was used as a positive control for USP8 and lung 
adenocarcinoma tissue with high SFN expression, which was used for a previous study (36), was 
used for SFN. Rabbit polyclonal USP8 antibody (Bethyl Laboratories, Montgomery, TX) and 
mouse monoclonal SFN antibody (Sigma-Aldrich) were used as the primary antibodies. 
 
2-3 Pyro-sequencing analysis  
Using a Qiagen QIAamp DNA mini kit (QIAGEN), genomic DNA was extracted from 
the PL16T, A549, PC9, HCC827, H1650, and H1975 cultured cell lines, and from 10 sets of 
fresh normal and tumorous human lung tissues resected surgically.  Primers used for PCR and 
pyro-sequencing were designed using QIAGEN software, PyroMark Assay Design 2.0.  The 
sequencing process, and allele quantification (AQ) / genotyping (SNP) assay, were performed 
using PyroMark24Q with suitable reagents from QIAGEN.  
 
2-4 Cell lines and culture conditions  
 The PL16T cell line was established in our laboratory from a surgically resected AIS of 
Pyro-sequencing primers    
USP8-Sequence primer GCGGGATAGGGAACC 
USP8-Forward (AQ) ATTATCATTCACCCACCAACACT 
USP8-Reverse (AQ) TCCTCTTGAATAGCCTGGGTTATA-Biotin 
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the lung (37). PL16T was maintained in MCDB153HAA (Wako, Osaka, Japan) supplemented 
with 2% FBS (Sigma-Aldrich, St. Louis, MO), 0.5 ng/ml human EGF (Toyobo, Tokyo, Japan), 5 
µg/ml human insulin (Wako), 72 ng/ml hydrocortisone (Wako), 40 µg/ml human transferrin 
(Sigma-Aldrich), and 20 ng/ml sodium selenate (Sigma-Aldrich). PC9 and A549 were purchased 
from RIKEN Cell Bank (Ibaraki, Japan) and H1650, H1975, HCC827 were purchased from the 
American Type Culture Collection (ATCC, Manassas, VA). The cells maintained in Dulbecco’s 
modified Eagle medium (DMEM) / F12 for A549, in RPMI 1640 for PC9, H1650, and HCC827, 
and in RPMI 1640 ATCC Modification (Thermo Fisher Scientific, Waltham, MA) for H1975. 
All mediums were supplemented with 10% FBS. The cells were cultured in a 5% CO2 incubator 
at 37°C and passaged every 3-4 days. 
 
2-5 Transfection of small interfering RNA (siRNA)  
USP8-specific or SFN-specific siRNAs from Thermo Fisher Scientific and a nucleic acid 
transfer agent, lipofectamine RNAiMAX (Thermo Fisher Scientific), were incubated together in 
OPTI-MEM reduced-serum medium (Thermo Fisher Scientific) for 15 min at room temperature 
to form a siRNA-lipofectamine complex. The medium containing the siRNA-lipofectamine 
complex was added to the cells to give a final siRNA concentration of 10 nM for A549 and 5 nM 
for PL16T, PC9, and H1975. The cells were incubated at 37°C in a 5% CO2 incubator for 24 or 
48 h and then further analyzed.        
siRNA sequences 
siUSP8 #1-Forward GGACAACCAGAAAGUGGAAUUCUAA  
siUSP8 #1-Reverse UUAGAAUUCCACUUUCUGGUUGUCC 
siUSP8 #2-Forward ACCGAAACUGUUAUCAGGAUGAUAU 
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siUSP8 #2-Reverse AUAUCAUCCUGAUAACAGUUUCGGU 
siUSP8 #3-Forward GCAGGAUUAUCAGGAUUCCUGUAUU 
siUSP8 #3-Reverse AAUACAGGAAUCCUGAUAAUCCUGC 
siSFN #1-Forward UCUCAGUAGCCUAUAAGAACGUGGU 
siSFN #1-Reverse ACCACGUUCUUAUAGGCUACUGAGA 
siSFN #2-Forward CCGUCUUCCACUACGAGAUCGCCAA 
siSFN #2-Reverse UUGGCGAUCUCGUAGUGGAAGACGG 
siSFN #3-Forward UGGAGAGAGCCAGUCUGAUCCAGAA 
siSFN #3-Reverse UUCUGGAUCAGACUGGCUCUCUCCA 
 
2-6 Transfection of expression vectors 
Expression vectors for full-length wild-type human USP8 was purchased from Addgene 
(Cambridge, MA). HA-ubiquitin was obtained from Prof. Yasunori Kanaho (University of 
Tsukuba, Japan). Plasmid DNA was purified using an EndoFree Plasmid Maxi kit (QIAGEN, 
Hilden, Germany). The day before transfection, PL16T cells were trypsinized, counted, and 
plated at 8 x 104 cells per well in 2 ml of complete growth medium onto 6-well plates to obtain 
50% to 80% confluence on the day of transfection. For each well of cells to be transfected, 2.8 
µg of plasmid DNA was diluted in 500 µl of OPTI-MEM reduced-serum medium, and then 8.3 
µl of Fugene HD (Promega, Madison, WI) was added, followed by incubation for 5 min at room 
temperature. I performed gentle mixing by rocking the plate back and forth. The cells were 
incubated at 37°C in a 5% CO2 incubator for 24 h, after which they were further analyzed. 
 
2-7 DNA plasmid constructs and point mutagenesis 
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Expression vectors for full-length wild-type human USP8 and both 14-3-3 epsilon and 
zeta were purchased from Addgene (Cambridge, MA). Construction of Flag-SFN and pSFN has 
been described previously (36). GFP-USP8 wild type, and GFP-USP8 C786S (DUB inactive) 
were obtained from Prof. Yasunori Kanaho (University of Tsukuba, Japan). Mutagenesis to 
create constructs encoding the S718C mutant form of USP8 was carried out with the PrimeSTAR 
Mutagenesis Basal kit (Takara, Shiga, Japan) in accordance with the manufacturer’s protocol. 
Mutagenesis of SFN was carried out by site-direct mutagenesis PCR. The primer information 
was list up below.  Sequences of all constructs were verified by Sanger sequencing. 
Primer for USP8 mutagenesis 
 
USP8 S718A-Forward TCCTACTGCTCCCCAGATATAACCCA 
USP8 S718A-Reverse TGGGGAGCAGTAGGAGCGCTTCAGTT 
 
 
Primer for SFN mutagenesis 
 
SFN K49A-Forward GCCTATGCAAACGTGGTGGGCGGC 
SFN K49A-Reverse CACGTTTGCATAGGCTACTGAGAG 
SFN R56A-Forward GGCCAGGCAGCTGCCTGGAGGGTG 
SFN R56A-Reverse GGCAGCTGCCTGGCCGCCCACCAC 
SFN R129A, Y130A-Forward TACTACGCAGCACTGGCCGAGGTGGCC 
SFN R129A, Y130A-Reverse GGCCAGTGCTGCGTAGTAGTCACCCTT 
     
2-8 Proliferation assay 
For analysis of cellular proliferation activity, a WST-1 (colorimetric) kit 
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(Roche Diagnostic, Mannheim, Germany) was used in accordance with the manufacturer’s 
protocol after siRNA transfection.         
 
2-9 Apoptosis assay 
After siRNA transfection for 48 h, all cells containing dead cells and lived cells were 
collected after trypsinization. The positive control for apoptosis analysis was cells treated with 
10 µM camptothecin (Sigma-Aldrich) for 24 h before collecting cells. The negative control was a 
lysate of viable non-treated PL16T cells. All cells were washed with 1x PBS and centrifuged at 
5000 rpm for 6 min at 4°C, twice. The supernatants were completely removed and the cell pellets 
were lysed with M-PER containing protease and phosphatase inhibitor. The lysates were 
centrifuged for 15,000 rpm for 10 min at 4°C and the supernatants were used for Western blot 
analysis. Anti-caspase3 and anti-cleaved caspase3 antibodies from Cell Signaling Technology 
were used for evaluation on apoptosis. 
 
2-10 Wound healing assay 
PL16T cells were transfected with siUSP8 or siSFN for 48 h in10 cm dish and 
trypsinized cells to transfer to 12-well plate to obtain confluent cells in the plate (n=4). After 24 
h, confluent cells were wounded by manual scratching with 200 µl pipette tips, washed with PBS, 
and incubated 37°C. The observation was performed 0, 3, 6, and 12 h after scratching but the 
wound was started to heal from 12 h and captured at 0 and 12 h. 
 
2-11 Quantitative real-time PCR analysis  
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To confirm the transfection efficiency and change in the EGFR and MET gene expression 
level affected by USP8 or SFN knockdown, PL16T cells were evaluated using quantitative real 
time RT-PCR. Total RNA was prepared from siUSP8 or siSFN-transfected PL16T using the 
RNeasy Mini Plus Kit (QIAGEN) and the quality was evaluated using an Agilent 2100 
Bioanalyzer (Thermo Fisher Scientific) as described above. One microgram of total RNA per 20 
µl of the reaction mixture was converted to cDNA using a High Capacity cDNA Reverse 
Transcription Kit (Thermo Fisher Scientific). Quantitative real time PCR was performed with 
SYBRVR Premix Ex TaqTM (Perfect Real Time; Takara Bio, Shiga, Japan) on a GeneAmpVR 
7300 Sequence Detection System (Thermo Fisher Scientific) in accordance with the 
manufacturer’s protocol. 
Primer for real-time PCR  
  
USP8-Forward CCTTTGACAAGAGCACGAAGTGAA 
USP8-Reverse ACATATGAACAGTGTTGGTGGGTGA 
SFN-Forward TCCACTACGAGATCGCCAACAG 
SFN-Reverse GTGTCAGGTTGTCTCGCAGCA 
 
2-12 Western blot analysis  
Total proteins were prepared on ice using Mammalian Protein Extraction Reagent (M-
PER; Thermo Fisher Scientific) for cultured cells or Tissue Protein Extraction Reagent (T-PER; 
Thermo Fisher Scientific) for fresh tissue containing a Halt protease and phosphatase inhibitor 
cocktail (Thermo Fisher Scientific). The lysates were centrifuged and the insoluble fraction was 
discarded. The total protein in the soluble lysates was measured using a BCA protein assay kit 
(Thermo Fisher Scientific). Total protein aliquots (20 µg) were mixed with 5x sample loading 
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buffer supplemented with DTT, denatured at 95°C for 5 min, and electrophoresed on 10% or 12% 
Mini-PROTEAN TGX Precast Gels (Bio-Rad Laboratories, Hercules, CA). Proteins were 
transferred to polyvinylidene difluoride membranes using an iBlot gel transfer system (Thermo 
Fisher Scientific). The blots were then blocked and probed with various antibodies. The 
antibodies used for Western blot analysis were obtained from various commercial sources as 
follows: USP8, phosphor-EGFR (Tyr1045), phosphor-EGFR (Tyr1068), phosphor-MET 
(Tyr1003), phosphor-Akt (Ser473), Akt, phosphor-ERK1/2 (Thr202/Tyr204), ERK1/2, 
phosphor-STAT3 (Tyr705), STAT3, Myc, p14-3-3 binding motif, and Flag from Cell Signaling 
Technology (Denvers, MA); EGFR and GFP from Medical & Biological Laboratories (Aichi, 
Japan); MET and SFN from Immuno-Biological Laboratories (Fujioka, Japan); HA from Roche 
Diagnostics; and β-actin from Sigma-Aldrich. After extensive washing, immunoreactivity was 
detected with specific secondary antibodies conjugated to horseradish peroxidase (Thermo Fisher 
Scientific). Protein bands were visualized using SuperSignal West Femto Maximum sensitivity 
substrate (Thermo Fisher Scientific) and images were captured on a ChemiDoc Touch Imaging 
System (Bio-Rad Laboratories). 
 
2-13 Co-immunoprecipitation (Co-IP)   
A549 cells were used for endogenous two proteins interaction by Co-IP. Since PL16T 
cells were difficult to detect endogenous interaction, the cells were transfected with appropriate 
plasmids before 24 h of protein extraction. The total protein was extracted using IP Lysis Buffer 
(Thermo Fisher Scientific) containing a Halt protease and phosphatase inhibitor cocktail 
(Thermo Fisher Scientific). The cell extracts were concentrated using Amicon Ultra 3k (Merck 
Millipore, Billerica, MA) by centrifugal filtration, supplemented with an appropriate antibody 
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and 40 µl of washed protein A magnetic beads (Cell Signaling Technology), and incubated at 
4°C overnight. The beads were subsequently pelleted on a magnetic separation rack for 15 s and 
washed 3 times using IP Lysis Buffer. The samples were then boiled at 95°C for 5 min to elute 
the immunocomplexed proteins. Levels of proteins in the elution products were assessed by 
Western blot analysis using the appropriate antibodies.  
 
2-14 Immunofluorescence (IF) 
The PL16T cells were plated on collagen-coated cover slides (Iwaki Biosciences, Tokyo, 
Japan) and fixed with 10% formalin. For immunofluorescence analysis, PL16T cells were 
incubated with appropriate antibody for 1 h at room temperature. After incubation with Alexa 
Fluor 488-labeled secondary antibody (Santa Cruz Biotechnology, Dallas, TX) or Alexa Fluor 
594-labeled secondary antibody (Cell Signaling Technology) for 1 h at room temperature, the 
cells were analyzed using a fluorescence microscope (Biorevo BZ-9000; Keyence, Osaka, Japan). 
The primary antibodies used for IF were obtained from various commercial sources as 
follows: anti-USP8 rabbit monoclonal antibody, anti-EEA1 rabbit monoclonal antibody from 
Cell signaling Technology, anti-LAMP1 mouse monoclonal antibody from Abcam, and anti-SFN 
rabbit polyclonal antibody from Immuno-Biological Laboratories, and anti-SFN mouse 
monoclonal antibody from Sigma-Aldrich.         
         
2-15 Detection of ubiquitinated proteins with Co-IP 
 PL16T cells were transfected with siRNA for 24 h followed by HA-ubiquitin for 24 h. 
After transfection, the cells were treated with 25 mM NH4Cl, a lysosomal inhibitor or 10 µM 
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MG132, proteasome inhibitor, for 4 h or 6 h, respectively at 37°C in a 5% CO2 incubator. The 
total protein was extracted using IP Lysis Buffer (Thermo Fisher Scientific) containing a Halt 
protease and phosphatase inhibitor cocktail (Thermo Fisher Scientific) and 10 mM N-
ethylmaleimide (NEM; Sigma-Aldrich), a deubiquitinase inhibitor. The cell extracts, containing 
0.5 mg of total protein, were supplemented with an appropriate antibody with 40 µl washed 
protein A or G magnetic beads (Cell Signaling Technology) and incubated at 4°C overnight. The 
beads were subsequently pelleted on a magnetic separation rack for 15 s and washed 3 times 
using IP Lysis Buffer. The samples were then boiled at 95°C for 5 min to elute the 
immunocomplexed proteins. The ubiquitinated proteins in the elution product were assessed by 
Western blot analysis using the appropriate antibodies.  
 
2-16 Detection of accumulated proteins at lysosome with IF 
 After siRNA transfection for 48 h, the cells on collagen-coated cover slides (Iwaki 
Biosciences, Tokyo, Japan) were treated with 25 mM NH4Cl, a lysosomal inhibitor for 4 h at 
37°C in a 5% CO2 incubator and fixed with 10% formalin. For detection of ubiquitinated 
proteins with immunofluorescence, PL16T cells were incubated with anti-EGFR (Medical & 
Biological Laboratories) or anti-MET (Cell signaling Technology), and together with anti-
LAMP1 (Abcam, Cambridge, MA) antibody for 1 h at room temperature. After incubation with 
Alexa Fluor 488-labeled secondary antibody (Santa Cruz Biotechnology, Dallas, TX) or Alexa 
Fluor 594-labeled secondary antibody (Cell Signaling Technology) for 1 h at room temperature 
in dark condition, the cells were analyzed using a fluorescence microscope (Biorevo BZ-9000; 
Keyence, Osaka, Japan).        
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2-17 Flow cytometry analysis 
Expression of EGFR and MET at the cell surface was determined by plating the cells in 
6-well plates at 48 h after siRNA transfection. The culture medium was replaced with serum-free 
medium for 16 h to block endocytosis of EGFR and MET. The cells were washed with PBS, 
detached with trypsin, and collected into tubes containing complete media on ice. The cells were 
washed twice with PBS containing 2% bovine serum albumin (BSA). The cells were incubated 
with phycoerythrin-conjugated (PE) monoclonal mouse IgG1 anti-EGFR (BioLegend, San Diego, 
CA), PE-conjugated monoclonal mouse IgG1 anti-MET (R&D Systems, Minneapolis, MN), or 
PE-conjugated anti-mouse IgG1 as an isotype control (BioLegend) on ice for 1 h in the dark. 
After two washes with PBS containing 2% BSA, the samples were analyzed with the BD 
FACSuite (BD Bioscience, San Jose, CA). Forward scatter/side scatter gating identified living 
cells.    
 
2-18 Cyclohexamide chase assay 
To block further protein biosynthesis of EGFR or MET, siRNA transfected PL16T cells 
were incubated in MCDB 153 HAA medium with 10 µg/ml cycloheximide (CHX; Sigma-
Aldrich) for time-course. After CHX treatment, the cell lysates were analyzed by Western blot 
analysis. 
         
2-19 Pulse-chase assay 
Pulse-chase assay was modified from previous study (38). After transfection of siUSP8 
or siSFN for 48 h in 10 cm collagen-coated dish, the cells were washed by PBS and incubated 
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with prewarmed DMEM medium without Met/Cys for 30 min at 37°C in a 5% CO2 incubator. 
For the pulse radioisotope, the cells were labeled with 35S-Met/Cys (10 µCi/ml) in DMEM 
medium without Met/Cys for 30 min at 37°C in a 5% CO2 incubator. This pulse-labeling step 
was used to label newly synthesized protein. The pulse was followed by a chase in which cells 
are further incubated with the unlabeled counterpart of the precursor used for labeling. For the 
chase labeled-protein, the metabolic labeled cells were washed with culture medium for 3 times 
and incubated with culture medium in time course 0, 2, 5, and 10 h. After chasing, the cells were 
washed once and the total protein was extracted by IP Lysis Buffer (Thermo Fisher Scientific) 
containing a Halt protease and phosphatase inhibitor cocktail (Thermo Fisher Scientific). The 
radioisotope-labeled EGFR proteins were isolated from other cellular proteins by IP and 
performed Western blot analysis. For quantitative determination of proteins, the membrane 
containing the radioisotope-labeled EGFR was scanned β–ray using Typhoon FLA7000 (GE 
Healthcare, Chicago, IL) image analyzing system. 
 
2-20 Statistical analysis  
Group results are expressed as mean ± SD. Data were compared between groups using 
the t test to calculate 2-tailed distributions and a paired t test. Differences at P *<0.05, **<0.01, 
and ***<0.001 were considered significant. SPSS 22 statistical software (SPSS, Chicago, IL) 
was used for IHC data analysis as follows. Correlations of clinicopathological features with 
USP8 or SFN expression were analyzed using the chi-squared test. Disease-free survival 
according to USP8 or SFN expression was examined using the Kaplan-Meier method, and the 
significance of differences between survival curves was evaluated using log-rank test.  
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3. Results 
 
3-1 Overexpression of USP8 and SFN in lung adenocarcinoma 
tissues 
USP8 and SFN are highly expressed in human lung adenocarcinoma tissues.  
 To evaluate the expression pattern of USP8 and SFN in human lung adenocarcinoma 
tissue, immunohistochemistry (IHC) was performed using 193 cases. Both USP8 and SFN were 
stained in the cytoplasm of formalin-fixed paraffin-embedded (FFPE) specimens from surgically 
resected lung adenocarcinoma, and that the expression was higher in tumor tissue than in normal 
lung tissue (Fig. 6A-6D). Consistent with the IHC results, Western blot analysis revealed that 
USP8 and SFN were highly expressed in tumor tissue relative to normal lung tissue (Fig. 6E).  
 
USP8 and SFN show correlative expression in human lung adenocarcinoma tissues.  
 To understand USP8 and SFN correlation in lung adenocarcinoma, USP8 and SFN both 
positive and both negative cases of IHC were divided. USP8 and SFN showed similar expression 
patterns in same localization of cytoplasm (Fig. 7A), and their expression was significantly 
correlated in 144/193 cases (74.6%, Fig. 7B).  
 
Expression of SFN is associated with patient’s prognosis. 
Expression of SFN was significantly associated with gender, Noguchi classification, 
pathological subtype, pathological stage, lymphatic permeation, and vascular invasion. Unlike 
SFN, USP8 expression was significantly associated with only the Noguchi classification for 
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small adenocarcinomas of the lung (2 cm or less in diameter, Table 1). Moreover, SFN positivity 
was significantly associated with a poorer outcome relative to SFN-negative cases (p=0.007, Fig. 
8B), whereas USP8 positivity was not (p=0.974, Fig. 8A). 
 
Mutation in USP8 is not found in lung adenocarcinoma tissues. 
 USP8 has 14-3-3 binding motif, which plays critical regulation roles. To investigate 
mutation in 14-3-3 binding motif of USP8, pyro-sequencing analysis was performed using lung 
adenocarcinoma cell lines and pair of fresh human normal and tumor lung tissues. Unlike 
Cushing’s disease (39), all cell lines including immortalized AIS cells and advanced stage lung 
adenocarcinoma cells and human lung tissue including normal and tumor had wild-type sequence 
of USP8 (Fig. 9).  
 
3-2 Functional analysis of USP8 and SFN in lung adenocarcinoma 
cells 
Selection of siRNA targeting USP8 or SFN in lung adenocarcinoma cells.  
To determine the best siRNA targeting USP8 or SFN for functional analysis, three 
different kinds of siRNAs were transfected into the A549 cells. All of the siRNAs successfully 
suppressed the expression of USP8 or SFN both at mRNA (Fig. 10A and 10D) and protein level 
(Fig. 10B and 10E). As siUSP8-I and siSFN-I showed the most marked suppression of cellular 
proliferation, they were selected and used for further analysis (Fig. 10C and 10F).  
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Knockdown of USP8 or SFN decreases cellular proliferation in lung adenocarcinoma cells. 
 To evaluate whether USP8 and SFN regulate cellular functions including cellular 
proliferation and apoptosis, siRNA-USP8, SFN, or a scrambled control (siCON) were transfected 
in immortalized AIS cells, PL16T and lung adenocarcinoma cell lines harboring EGFR mutation, 
PC9 and H1975. Knockdown of USP8 or SFN significantly reduced the proliferation of all lung 
adenocarcinoma cells harboring EGFR mutation, similarly to A549 cells (Fig. 11). Since PL16T 
was the most effective reduction of cellular proliferation in knockdown of USP8 or SFN, PL16T 
cells were chosen for further functional assays (Fig. 11). 
 
Knockdown of SFN or USP8 induces apoptosis in PL16T.  
 To examine reduction of proliferation was caused by induction of apoptosis, alteration of 
cleaved caspase 3, which is a representative apoptotic protein, was analyzed by Western blot 
analysis. Correlated with proliferation result, knockdown of USP8 or SFN in PL16T cells led to 
induction of apoptosis (Fig. 12A).  Moreover, to investigate migration effect of knockdown of 
USP8 or SFN, wound healing assay was examined. Unlike SFN, knockdown of USP8 delayed 
recovery of scratch compared with siCON, indicating that USP8 regulates migration in PL16T 
cells (Fig. 12B). 
 
3-3 USP8 regulates RTKs and SFN expression in lung 
adenocarcinoma cells 
USP8 interacts both RTKs and SFN in lung adenocarcinoma cells. 
 USP8 has been reported to regulate RTKs such as EGFR and MET in advanced lung 
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adenocarcinoma cells (21). To confirm the interaction between USP8 and RTKs in A549 with 
high expression of SFN, co-IP was performed and USP8 interacted with SFN and RTKs such as 
EGFR and MET (Fig. 13A). Endogenous interaction between USP8 and RTKs as well as SFN 
was difficult to detect in PL16T cells. However, after overexpression of USP8, USP8 showed to 
interact with EGFR, and MET, but not with SFN due to low expression of SFN in PL16T cells 
(Fig.13B). 
 
Overexpression of USP8 up-regulates EGFR expression in PL16T.  
 To investigate whether overexpression of USP8 regulates RTKs and SFN expression, 
Western blot analysis was performed in PL16T cells.  Overexpression of USP8 increased EGFR 
expression but did not alter MET and SFN expression. Among downstream signaling factors, 
pAKT was slightly increased by overexpression of USP8 (Fig. 14) 
      
Knockdown of USP8 down-regulates RTKs and SFN expression by posttranslational 
modification in PL16T.  
 To understand the function of USP8 in PL16T cells, siRNA-USP8 was transfected and 
the expression levels of SFN, RTKs, and their downstream factors were examined. Knockdown 
of USP8 down-regulated the level of SFN protein (Fig. 15A). Moreover, knockdown of USP8 
decreased the expression of RTKs such as EGFR, pEGFR Y1068 (cellular proliferation-related 
phosphorylation site), and MET, and mainly decreased STAT3 and AKT signaling, in 
accordance with the results of the cellular proliferation assay (Fig. 15A).  
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Knockdown of USP8 down-regulates membrane surface of RTKs in PL16T. 
 Consistent with the results of Western blot analysis, surface EGFR and MET expressions 
were examined by flow cytometry. After serum starvation for excluding endosome RTKs, 
surface RTKs were directly stained with fluorescent conjugated antibody. Surface EGFR and 
MET were decreased significantly after USP8 knockdown (Fig. 15B and 15C).  This is indicated 
that knockdown of USP8 regulates surface RTKs expression levels.     
 
Knockdown of USP8 enhances ubiquitinated RTKs in PL16T.  
  To clarify whether knockdown of USP8 blocks recycling of RTKs, ubiquitinated EGFR 
and MET for RTK degradation were examined using co-IP after transfection with siRNA-USP8. 
Ubiquitinated EGFR and MET were detected after treatment with the lysosomal inhibitor, NH4Cl, 
for 4 h to evaluate the accumulation of ubiquitinated proteins at lysosomes. Knockdown of USP8 
strongly induced accumulation of poly-ubiquitinated EGFR and MET, as revealed by Western 
blot analysis (Fig. 16).  
 
Knockdown of USP8 accumulates ubiquitinated RTKs at lysosome in PL16T.  
 To investigate where ubiquitinated EGFR and MET increase in the cell, IF under 
treatment of lysosomal inhibitor, NH4Cl was performed and showed co-localization of EGFR 
and MET at lysosomes that were immunostained with antibody against LAMP1, a lysosomal 
marker (Fig. 17A and 17B). Consist with ubiquitinated EGFR or MET in co-IP results, 
knockdown of USP8 enhanced accumulation of EGFR and MET at lysosome for their 
degradation. 
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3-4 SFN regulates RTKs and USP8 expression in lung 
adenocarcinoma cells 
SFN interacts both RTKs and USP8 in lung adenocarcinoma cells. 
 A previous study using co-IP/MS analysis had identified various SFN binding partners, 
including EGFR, in nasopharyngeal carcinoma (40). To investigate SFN binding with RTKs in 
lung adenocarcinoma cells, co-IP was performed. As had been shown previously, endogenous 
SFN was found to interact with USP8 and RTKs including EGFR and MET in A549 cells (Fig. 
18A). Since endogenous interaction between SFN and RTKs was difficult to detect in PL16T, 
SFN plasmid was transfected to PL16T cells, which immortalized AIS cell line showed low 
expression of SFN. Overexpression of SFN was shown interaction with EGFR or MET, but not 
with USP8 (Fig. 18B). 
 
Overexpression of SFN up-regulates EGFR expression in PL16T.  
 To investigate whether overexpression of SFN regulates RTKs and USP8 expression, 
Western blot analysis was performed in PL16T cells.  Similarly to overexpression of USP8, 
overexpression of SFN increased EGFR and USP8 expression but did not alter MET. Among 
downstream signaling factors, pSTAT3 and pERK was increased by overexpression of SFN (Fig. 
19). 
 
Knockdown of SFN regulates RTKs and USP8 expression in PL16T.  
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 To demonstrate that SFN regulates the expression of USP8 and RTKs, PL16T cells were 
transfected with siRNA-SFN. Knockdown of SFN increased the total expression of EGFR 
protein, whereas total MET and downstream factors such as pSTAT3 were decreased (Fig. 20A). 
RTKs have various phosphorylation sites, which operate in degradation- or cellular proliferation-
related signaling. Whereas pEGFR Y1068 is associated with cellular proliferation, EGFR and 
MET also contain phosphorylation sites at Y1045 and Y1003, respectively, where c-Cbl, E3 
ligase conjugates ubiquitin, leading to protein degradation. I found that pEGFR Y1045 and 
pMET Y1003 showed higher after SFN knockdown than control (Fig. 20A), indicating that 
knockdown of SFN strongly induces degradation signaling of RTKs. The up-regulation of total 
EGFR after transfection with siRNA-SFN might be explained by an increase of pEGFR Y1045, 
which is destined for degradation.  
         
SFN directly regulates and stabilizes USP8 expression in PL16T.  
 A rescue experiment revealed that the reduction of USP8 expression after SFN 
knockdown was abrogated by overexpression of SFN (Fig. 20B), indicating that SFN directly 
regulates the expression of USP8 protein. As supportive evidences for that SFN stabilizes USP8 
expression, knockdown of SFN enhanced accumulation of poly-ubiquitinated USP8, which is 
indicated by higher molecular size of original with smear band, under treatment of MG132, a 
proteasome inhibitor, for 4 h in time-dependent manner (Fig. 20C). 
 
Knockdown of SFN accumulates ubiquitinated RTKs at lysosome in PL16T.  
Next, to demonstrate whether SFN is involved in degradation of RTKs, similarly to USP8, 
ubiquitinated EGFR or MET were detected in PL16T under treatment of lysosomal inhibitor, 
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NH4Cl. Expression of ubiquitinated EGFR and MET after knockdown of SFN was clearly higher 
than in the controls (Fig. 21). Knockdown of SFN induced the accumulation of EGFR and MET 
at lysosomes that were immunostained with antibody against LAMP1, a lysosomal marker, being 
destined for degradation (Fig. 22) 
 
Knockdown of SFN reduced half-life of RTKs in PL16T.  
 Consistent with the fact that knockdown of SFN regulates RTKs expression, the half-life 
of EGFR and MET after knockdown of SFN was shorter than in controls treated with CHX in 
PL16T cells (Fig. 23A).  Notably, EGFR expression in siSFN was higher expression at 0 h but 
more quickly decreased until 12 h compared with siCON. To confirm this result, pulse-chase 
assay for EGFR using radioisotope was implemented. Consistent with CHX chase assay, 
knockdown of SFN quickly removed radioisotope labeled EGFR (Fig. 23B). 
 
3-5 SFN and USP8 collaboratively regulate RTKs expression in lung 
adenocarcinoma cells 
USP8 specifically interacts with SFN among 14-3-3 proteins at endosome in PL16T.  
 Previous studies have found that USP8 interacts with 14-3-3 proteins in embryonic 
murine brain (41) and T-cells (42), but not in lung. To clarify whether USP8 binds specifically to 
SFN in lung, co-IP was carried out to examine the interaction of USP8 with SFN, 14-3-3 epsilon, 
or 14-3-3 zeta, separately. Unlike previous observations, the results indicated that among three 
kinds of 14-3-3 proteins, only SFN bound specifically to USP8 in PL16T cells (Fig. 24). In 
addition, IF results were shown that USP8 and SFN were co-localized in the cytoplasm, 
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particularly in both the early and late endosome, in PL16T cells (Fig. 25). These data indicate 
that USP8 interacts with SFN in endosomes. 
         
Mutation of 14-3-3 binding motif in USP8 impairs interaction with SFN and down-regulates 
expression of RTKs and their downstream factors in PL16T.  
 The 14-3-3 binding motif of USP8 (RSYSSP) is essential in order for USP8 to interact 
with the 14-3-3 family, and S718 of the 14-3-3 binding motif in USP8 is a critical biological 
phosphorylation site (Fig. 4) (39). To elucidate whether SFN regulates USP8 activity in RTK 
recycling, a mutant form of USP8, S718C, was generated which shows impaired binding with 
SFN. Co-IP was performed after overexpression of either the wild-type or mutant USP8 to 
examine the resulting interaction with SFN. The interaction of the mutant USP8 with SFN was 
obstructed, and phosphorylation at the S718 residue was also lost (Fig. 26A), signifying that 
phosphorylation of USP8 at this site is crucial for SFN binding. 
 Moreover, PL16T cells were transfected individually with the wild-type USP8, the 
mutant USP8 S718C, and the mutant USP8 C786S, which has a point mutation in the catalytic 
domain causing inactivation of deubiquitination. As expected, the mutant USP8 S718C 
decreased the expression of RTKs including EGFR and MET as well as downstream factors 
including pAKT and pSTAT3, in comparison with the wild-type USP8 (Fig. 26B).  
Collectively, these findings suggest that binding of SFN with USP8 is essential for 
deubiquitination of RTKs in PL16T cells. 
 
Mutation of ligand recognition site in SFN impairs interaction with USP8 and negatively 
regulates RTKs in PL16T.  
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 According to previous study, SFN has four important residues, Lys49, Arg56, Arg129, 
and Tyr130, for recognizing of phospho-target proteins such as USP8 in lung adenocarcinoma 
(10). These positive charged residues specifically interacts with negative charged phospho-Ser of 
ligands. To demonstrate whether these multiple four residues or single specific residue is 
required for SFN association with USP8, SFN mutants were generated multiple mutant and 
single mutant such as K49A, R56A, and R129A combined with Y130A, respectively and applied 
to co-IP. All mutants almost abolished interaction with USP8 (Fig. 27A and 27B). Because of 
impairment of binding with USP8 and SFN by mutation of biding sites, co-transfection of mutant 
USP8 and SFN decreased RTKs expression compared with co-transfection of wild-type USP8 
and SFN (Fig. 27C and 27D). These results showed that the four residues of SFN are very 
responsible for USP8 association and SFN-USP8 complex plays an important regulation role of 
RTKs stabilization.   
 
Phosphorylation of USP8 is regulated by Serine/Threonine kinase and phosphatase. 
Panner A. et. al. has reported that enzymatic activity of USP8 is dependent on AKT, a 
serine/threonine-specific protein kinase (43). To reveal the involvement of AKT on regulation of 
USP8 phosphorylation on its 14-3-3 BM, A549 cells were treated with AKT inhibitor, 
LY294002. Treatment of LY294002 apparently decreased USP8 phosphorylation on 14-3-3 BM 
and also impaired binding of USP8 with SFN, showing that AKT is one of the key kinases for 
USP8 regulation (Fig. 28A). In contrast, specific phosphatase for USP8 is still unknown. As a 
best-known phosphatase with strong effect, we focused on PP1 or PP2a and treated cells with 
their inhibitor, okadaic acid. Expectedly, treatment of okadaic acid led to a marked increase of 
USP8 phosphorylation on 14-3-3 BM and binding of USP8 with SFN (Fig. 28B). 
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4. Discussion 
 In this study, immunohistochemically, both USP8 and SFN showed higher expression in 
lung adenocarcinoma than in normal lung tissue, and their expressions levels were mutually 
correlated in lung adenocarcinoma tissues (Fig. 6 and Fig. 7). Clinically, the level of SFN 
expression was associated with patient outcome, but that of USP8 is not (Table 1 and Fig. 8). 
This discrepancy will be explained that the biological effect of USP8 might be included in that of 
the multi-functional protein, SFN, and the expression of USP8 itself may not influence the final 
outcome. 
 Moreover, knockdown of SFN or USP8 similarly suppressed cellular proliferation and 
induced apoptosis in lung adenocarcinoma cell lines in vitro (Fig. 10 and Fig. 11). These 
phenomena were induced most markedly in the PL16T cell line, which was established from AIS, 
an extremely early-stage form of adenocarcinoma, in comparison with other cell lines derived 
from advanced adenocarcinoma (Fig. 11). Previous study had found that DNA demethylation-
triggered abnormal overexpression of SFN is an early event in the malignant progression of lung 
adenocarcinoma similarly to genetic alteration of EGFR, K-RAS, and p16 (3, 11, 36). Since 
overexpressed SFN induces stabilization of USP8 protein (Fig. 19 and Fig. 20), alteration of 
USP8 might be also one of the oncogenic events induced by SFN at the early stage of lung 
adenocarcinoma.  
 As reported before, I confirmed that USP8 binds and regulates EGFR and MET to 
accelerate their deubiquitination (Fig. 13 and Fig. 16). Knockdown of USP8 suppressed the 
expression of EGFR, pEGFR Y1068  (a cellular proliferation-related site), MET, pSTAT3, and 
pAKT, and this effect was thought to be associated with the accelerated ubiquitination of EGFR 
and MET. After transfection with siRNA-USP8, membrane-associated EGFR and MET were 
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ubiquitinated and accumulated in lysosomes (Fig. 15 and Fig. 16-17). On the other hand, SFN 
was also shown to be a binding partner of EGFR and MET (Fig. 18), and knockdown of SFN 
suppressed the expression of MET and pSTAT3, although total EGFR did not show any 
suppression (Fig. 20).  However, pEGFR Y1045 and pMET Y1003 (sites related to protein 
degradation) were upregulated and these phenomena indicated that knockdown of SFN strongly 
induced degradation signaling of EGFR and MET. The increase of EGFR expression in Fig. 20A 
due to suppression of SFN is thought to have been due to binding of SFN to the other binding 
partners, thus influencing EGFR expression. Additionally, I can not exclude the possibility that 
knockdown of SFN might lead to recovery of EGFR biosynthesis followed by a decrease of cell 
viability, as feedback regulation for cell survival. 
 Moreover, knockdown of USP8 or SFN increased the amount of ubiquitinated RTKs 
(Fig. 16 and Fig. 21).  This similar phenomenon in knockdown of USP8 and SFN imply their 
functionally close association. Thus, I confirmed that USP8 is a unique binding partner of SFN, 
unlike other members of the 14-3-3 protein family (Fig. 24) and co-localized in early- and late-
endosome (Fig. 25). Additionally, mutant USP8 S718C and mutant SFN, which are unable to 
bind to USP8 and SFN each other, impaired the stability of RTKs (Fig. 26 and Fig. 27). These 
findings lend support to the possibility that SFN promotes USP8 activity, causing RTK 
stabilization in lung adenocarcinoma.  
 Mizuno et al. and Dufner et al. have identified 14-3-3 epsilon, zeta, gamma, and beta, but 
not sigma (SFN), as USP8 binding partners (17, 42). 14-3-3 epsilon and beta, which are highly 
expressed in mammalian brain (6), inhibit USP8 activity in Cushing’s disease (44-46) and mouse 
T-cells (42) by blocking the cleavage of USP8, leading to hyperactive deubiquitination of EGFR. 
Moreover, mutations of USP8 in Cushing’s disease frequently occur at the 14-3-3 binding motif, 
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leading to up-regulation of EGFR and subsequent hyperproduction of ACTH, the hallmark of 
Cushing’s disease (39). In contrast to Cushing’s disease, any somatic mutation did not revealed 
at the 14-3-3 binding motif of USP8 in lung adenocarcinoma tissue, or any fragmentary form of 
USP8 in lung adenocarcinoma cells (Fig. 9).  
 Previous studies have indicated that each of the 14-3-3 member proteins has unique 
functions, which are context-dependent and also organ- or tissue-dependent (6). SFN in 
particular is evolutionarily distinct from all of the other 14-3-3 proteins from the viewpoint of 
sequence conservation (5), and shows the closest association with lung cancer (47). In this regard, 
abnormal activation of USP8 induced by SFN is a unique and tissue-specific phenomenon in 
lung adenocarcinoma.  
Post-translational modification including ubiquitination and deubiquitination is the key 
mechanism for regulation of degradation mediated by cell surface receptors and ligands (13). 
USP8 directly deubiquitinates and consequently recycles RTKs to their lysosomal degradation, 
thereby maintaining oncogenic signaling (17, 23). USP8 enzymatic activity is dependent on 
phosphorylation by c-Src, a non-receptor tyrosine kinase (48), and AKT, a serine/threonine-
specific protein kinase (43).  Similarly, here we suggested that AKT and also several 
phosphatases might be involved in regulation of USP8 phosphorylation (Fig. 28). Since AKT is 
usually up-regulated in tumor cells because of various stimulation including RTKs stabilization 
through USP8 activation, it is possible that over-activation of AKT might accelerate binding of 
phospho-USP8 with SFN. Based on the fact that phospho-USP8 binds to SFN, overexpression of 
SFN in lung adenocarcinoma might promote interaction with USP8 via its phosphorylation and 
induce a conformational change in USP8 that increases its enzymatic activity and stability (8) 
(Fig. 29). Recently, a similar mechanism for regulation of USP8 was reported for Tiam1, a Wnt-
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responsive gene, which is phosphorylated by AKT, allowing it to bind with 14-3-3 and thus 
rendering it stable, thereafter accumulating to promote cell growth and proliferation (49). 
 Many molecular targeting drugs have been developed for advanced lung 
adenocarcinomas harboring EGFR mutation or ALK rearrangement (50, 51). Although TKIs for 
EGFR and EML4-ALK suppress tumor cell growth and are initially very effective, most tumors 
subsequently aquire resistance to the drugs. Byun et al. reported that a USP8 inhibitor suppressed 
both growth and tumor formation by both TKI-resistant and -sensitive NSCLC cells, and 
suggested that USP8 might be a preferable theraputic target for overcoming aquired resistance 
(21). However, it would be expected that any USP8 inhibitor might dysregulate the physiological 
important functions of USP8 in normal tissues, causing severe side effects. On the other hand, 
SFN shows high tumor-specific expression and induces aberrant USP8 activation in lung 
adenocarcinoma. Therefore, a SFN inhibitor would be more a selective and desirable therapeutic 
target for lung adenocarcinoma than USP8, with the possibility of effectiveness against TKI-
resistant tumors. 
 Low-dose CT screening trials have suggested that the number of adenocarcinomas 
detectable at an early stage, such as AIS and minimally invasive adenocarcinoma (MIA), has 
been increasing. In comparison to the standard treatments for advanced adenocarcinoma, no 
treatments for AIS and MIA, apart from surgical resection, have yet been established. Moreover, 
it is still being debated whether the use of surgery for AIS is a suitable approach, or whether it 
constitutes over-treatment. Here, I have shown that SFN regulates USP8 function, even in an 
AIS cell line, PL16T, in vitro. These results suggest that SFN holds promise as a therapeutic 
target for not only advanced, but also very early-stage lung adenocarcinoma. 
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5. Perspectives  
Oncogenic function of SFN-USP8 complex and its application in 
diagnosis and treatment of lung adenocarcinoma  
 Abnormalities of plasma membrane receptors such as RTKs in cancer cells are widely 
acknowledged and known to cause overexpression of them. Moreover, lung adenocarcinoma is 
considered to progress in a stepwise manner with the different 5-year survival rate and various 
genetic alterations. Particularly, mutation of RTKs including EGFR or MET is one of the most 
important alteration arising from atypical adenomatous hyperplasia (AAH) or AIS, precancerous 
or early stage of lung adenocarcinoma. 
 However, most lung adenocarcinoma patients with poor prognosis harbor mutation of 
RTKs and undergo molecular targeted therapies in advanced stage. In this period, it is difficult to 
cure it completely, and most tumors acquire resistance to the drugs by second mutation of 
targeted proteins. Therefore, research focus had been changing to study and identify specific 
molecular target that can be applied for detection and treatment of at an early stage.   
 In the present study, I demonstrated the molecular mechanism underlying the binding of 
SFN to USP8 in lung adenocarcinoma cells, resulting in RTK stabilization. It is suggested that 
SFN is one of the target candidates for diagnosis and treatment of early stage lung 
adenocarcinoma. 
 A recent report was worthy of notice that SFN can be released into the extracellular 
environment physiologically through exosomes (52), which play important roles in cellular 
communication by containing diverse biomarkers implying cell condition, and the aberrant 
exosomal process was observed in various cancer cells including lung cancer (53, 54).  
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Generally, tumor cells can secrete more exosomes than normal cells, but more 
importantly, the content of exosomes from tumor cells is distinct, which has clinical significance 
(55). Exosomes produced by normal as well as tumor cells are released into extracellular space 
and present in all human body fluids including blood, urine, cerebrospinal fluid, and ascites (56). 
Therefore, SFN in exosomes can be an attractive and useful diagnostic biomarker for early-stage 
lung adenocarcinoma using body fluids such as serum or bronchoalveolar lavage. 
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6. Conclusions 
Unlike the current treatment strategy for advanced adenocarcinomas, no therapeutic 
approach for early-stage lung adenocarcinomas such as AIS has yet been established, except 
surgical resection. SFN is a novel and unique oncogene that accelerates tumor initiation and 
early malignant progression of lung adenocarcinoma. In this study, I investigated the mechanism 
underlying the interaction of SFN with its binding partner protein, USP8, which contributes to 
stabilization of RTKs such as EGFR and MET through deubiquitination activity. SFN was 
shown that facilitates aberrant activation of USP8 and subsequently protects RTKs from 
lysosomal degradation in an AIS cell line. These new findings suggest that SFN may be central 
to the development of a useful therapeutic strategy for both early and advanced lung 
adenocarcinomas. 
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Fig. 1. Stepwise progression of adenocarcinoma with molecular alterations. 
 Noguchi classification is closely associated with stepwise progression of peripheral type adenocarcinoma, which is 
subcategorized into type A to C. Lung adenocarcinoma develops and progresses to invasive carcinoma through 
AAH, AIS, and MIA. The first period, AAH progresses to AIS, frequently occur gene mutation such as EGFR 
mutation or amplification, K-RAS mutation, and anti-apoptotic abnormality such as p16 tumor suppressor gene 
inactivation. The second period, AIS progresses to invasive adenocarcinoma, acquire various additional genetic 
alteration such as p53 mutation, allelic imbalances at 11p11-p12, 17p12-p13, and 18p11 (3). 
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Fig. 2. Frequencies of driver oncogene aberrations in lung adenocarcinoma.  
The data were obtained from a Japanese cohort (n=319) and modified from Saito M et. al. ,Cancer science, 2016, 
107,6, 713-720. 
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Fig. 3. 14-3-3 cladogram and SFN structure. 
(A) 14-3-3 sigma (SFN) is evolutionarily distinct from clades encompassing all other 14-3-3 proteins (5). (B) SFN 
can be observed as homodimer form, which may be required for SFN function (10).  
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Fig. 4. Human USP8 protein structure. 
The human USP8 has a theoretical molecular weight of 130 kDa and a pI of 8.7. USP8 contains a deubiquitinase 
catalytic (DUB) domain (residues 774-1106), a microtubule interacting and transport (MIT) domain (residues 8-137), 
a rhodanese-like (Rho) domain (residues 185-310), two Src homology 3-(SH3) binding domains (SH3-I residues, 
405-413; SH3-II residues, 700-708), and 14-3-3 binding motif (residues 715-720). The function of USP8 
deubiquitinase activity may be regulated by phosphorylation and by specific protein-protein interaction (57). 
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Fig. 5. RTKs signal transduction. 
(A) Following ligand binding, RTKs such as EGFR and MET get activated and dimerized via phosphorylation. One 
phosphorylation site at Y1045 for EGFR and Y1003 for MET, serves a docking site for the ubiquitin ligase Cbl. The 
ubiquitinated RTKs are rapidly transported to early endosome by endocytosis process and eventually degraded at 
lysosome. This process is down-regulation pathway of RTKs. (B) On the other hand, RTKs also have another 
phosphorylation site such as Y1068 for EGFR and Y1234/Y1235to activate downstream signaling transduction, 
such as PI3K/AKT/mTOR, RAS/RAF/MEK/ERK, and JAK/STAT3, which are critical for cancer cell survival and 
proliferation (58, 59). 
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Fig. 6. The expressions of USP8 and SFN in tumor tissue. 
 (A-D) Immunohistochemistry (IHC) for USP8 and SFN was performed using formalin fixed and paraffin 
embedded (FFPE) specimens of 193 cases of surgically resected lung adenocarcinoma. Normal lung tissues were 
almost negative for USP8 (A) and SFN (C), whereas tumorous tissues showed higher expression of USP8 (B) and 
SFN (D) mainly in the cytoplasm. (E) Western blot analysis of fresh lung tissue demonstrated expression of USP8 
and SFN in both normal and tumorous tissue, but the expression level in tumor was higher than normal. N, normal 
lung tissue; T, tumorous lung tissue; #1 and #2, case number. 
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Fig. 7. USP8 and SFN show a corresponding increase of expression in human lung 
adenocarcinoma tissues. 
(A) USP8 and SFN were detected mainly in the cytoplasm of the tumor cells with a similar staining pattern. Normal 
lung tissue was almost negative for USP8 (A-1) and SFN (A-3), whereas tumor tissue showed higher expression of 
USP8 (A-2) and SFN (A-4). (B) Correlation analysis of USP8 and SFN was performed using the IHC results. 
Correlated cases were significantly more than uncorrelated cases in USP8 and SFN IHC (chi-squared test, 
***p<0.001).  
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Table 1. SFN or USP8 expression in relation to clinicopathological features of patients with lung 
adenocarcinoma. 
Clinicopathological 
 Features 
SFN Expression Total  
patients 
P-
value 
USP8 Expression Total  
patients 
P-
value Negative Positive Negative Positive 
IHC 84 109 193   93 100 193   
Age (yr) 
   
0.822 
   
0.429 
≤60 22 27 49 
 
26 23 49 
 >60 62 82 144 
 
67 77 144 
 Gender 
   
0.032 
   
0.191 
Female 43 39 82 * 44 38 82 
 Male 41 70 111 
 
49 62 111 
 Noguchi classification 
   
0.003 
   
0.039 
Type A 8 0 8 ** 8 0 8 * 
Type B 9 6 15 
 
7 8 15 
 Type C' 6 3 9 
 
5 4 9 
 Type C 22 20 42 
 
22 20 42 
 Type D 5 10 15 
 
6 9 15 
 Type F 1 2 3 
 
0 3 3 
 Total 51 41 92 
 
48 44 92 
 Pathological Subtype 
   
<0.001 
   
0.313 
AIS 19 6 25 *** 17 8 25 
 MIA 7 5 12 
 
7 5 12 
 Invasive 
adenocarcinoma 
          Lepidic 18 31 49 
 
19 30 49 
   Acinar 10 11 21 
 
9 12 21 
   Papillary 13 13 26 
 
13 13 26 
   Micropapillary 2 2 4 
 
3 1 4 
   Solid 5 31 36 
 
15 21 36 
 IMA 10 10 20 
 
10 10 20 
 Pathological Stage 
   
0.046 
   
0.192 
Stage I 65 65 130 * 64 66 130 
 Stage II 9 24 33 
 
11 22 33 
 Stage III 10 18 28 
 
17 11 28 
 Stage IV 0 2 2 
 
1 1 2 
 Lymphatic permeation       0.004       0.413 
Ly0 63 60 123 ** 62 61 123 
 Ly1 21 49 70 
 
31 39 70 
 Vascular invasion 
   
<0.001 
   
0.872 
V0 63 50 113 *** 55 58 113 
 V1 21 59 80   38 42 80   
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Fig. 8. SFN expression is associated with the outcome of the lung adenocarcinoma patients. 
Disease-free survival (DFS) depicted as Kaplan-Meier curves showing the correlation between outcome and SFN or 
USP8 expression. Positive expression of SFN was associated with a poorer outcome than negative expression 
(p=0.007), but USP8 expression did not show the correlation (p=0.974). 
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Fig. 9. Mutant of USP8 in 14-3-3 binding motif undiscovered in lung adenocarcinomas. 
(A and B) Genomic DNA was extracted from the PL16T and A549 cell lines and (C and D) from fresh human 
normal lung and tumor tissues.  The sequencing was analyzed by Pyro-Mark software, which automatically 
calculated each sequence percentage as a quantitative value and genotype. These pyro-sequencing results are 
representative data for 9 cultured cell lines and 10 sets of normal and tumor tissue specimens. 
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Fig. 10. Knockdown efficiency of siRNA-USP8 or -SFN in mRNA and protein levels and 
cellular proliferation. 
A549 was transfected with three kinds of siRNA-USP8 (A-C), siRNA-SFN (D-F) or scrambled 
siRNA. Knockdown efficiency was confirmed at the mRNA and protein levels. (A and D) Total 
RNA was extracted from the cells after siRNA transfection for 24 h. USP8 or SFN mRNA were 
examined by real-time RT-PCR, and 18S was used as an internal control. (B and E) Total protein 
was extracted from the cells after siRNA transfection for 48 h. USP8 or SFN protein were 
analyzed by Western blot analysis. β-Actin was used as a control to verify equal loading of 
protein (20 µg). (C and F) Cellular proliferation was examined using WST-1 assay after siRNA 
transfection for 48 h. Among three siRNA sequences, the most effective siRNA-USP8-I and 
siRNA-SFN-I, were selected for further analysis. 
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Fig. 11. Knockdown of USP8 or SFN regulates proliferation of lung adenocarcinoma cell 
lines. 
Cellular proliferation was tested by WST-1 using PL16T (immortalized AIS cells) and the adenocarcinoma cell lines, 
PC9 and H1975, after siUSP8-I or siSFN transfection for 48 h. 
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Fig. 12. Knockdown of USP8 or SFN regulates apoptosis and migration of PL16T. 
(A) Expression of caspase 3 and cleaved caspase 3 as representative apoptosis-related proteins was analyzed using 
protein extracted for 48 h after siRNA transfection into PL16T. The positive control was pretreated with 10 µM 
camptothecin for 24 h at 37°C in a 5% CO2 incubator before protein extraction. (B) In vitro migration activity was 
examined 12 h after scratch onto confluent cells. Knockdown of USP8 decreased wound healing activity compared 
to siCON or siSFN. PL16T, immortalized AIS cells. 
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Fig. 13. USP8 binds with SFN and RTKs in lung adenocarcinoma cell lines. 
(A) Endogenous interaction between USP8 and SFN or RTKs such as EGFR and MET was examined by Co-IP in 
A549 cells. As a negative control (NC), the cell lysate and protein A magnetic beads were incubated without 
antibody for 1 h at 4°C. (B) Co-IP using Flag antibody was performed after overexpression of Flag-USP8 in PL16T 
cells. As a negative control, the cell lysate and protein A with IgG antibody were incubated for 1 h at 4°C. The 
eluted IP sample was subjected to Western blot analysis using the indicated antibodies. PL16T, immortalized AIS 
cells. 
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Fig. 14. Overexpression of USP8 enhances stabilization of RTKs in PL16T. 
Flag-USP8 wild type was transfected into PL16T and expression of RTKs and downstream factors was analyzed by 
Western blot analysis. EGFR has mainly two phosphorylation sites, Y1045 for degradative pathway and Y1068 for 
proliferation-mediated pathway. MET Y1003 is a phosphorylation site for degradative pathway. β-Actin was used as 
a control to verify equal loading of protein (20 µg). PL16T, immortalized AIS cells. 
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Fig. 15. Knockdown of USP8 downregulates SFN, surface RTKs, and the downstream 
factors in PL16T. 
(A) Transfection efficiency of siUSP8 was evaluated by USP8 expression. Expression of SFN, RTKs, and the 
downstream factors were analyzed by Western blot analysis. β-Actin was used as a control to verify equal loading of 
protein (20 µg).  EGFR (B) and MET (C) expression at the cell surface was verified by flow cytometry after 
transfection with siUSP8 under serum starvation. The column chart was drawn using the mean value of PE-A (n=3, 
t-test ***p<0.001). PL16T, immortalized AIS cells. 
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Fig. 16. Knockdown of USP8 increases ubiquitinated RTKs in PL16T. 
Expression of ubiquitinated EGFR and MET was assessed by immunoprecipitation after transfection with siUSP8 
accompanying the overexpression of HA-ubiquitin. The cells were treated with 25mM NH4Cl (a lysosomal inhibitor) 
for 4 h, leading to accumulation of ubiquitinated EGFR or MET at the lysosome. PL16T, immortalized AIS cells. 
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Fig. 17. Knockdown of USP8 induced accumulation of RTKs at lysosome in PL16T. 
After siUSP8 transfection, ubiquitinated EGFR and MET, which were destined for lysosomal degradation, were 
assessed by IF employing LAMP1 (lysosomal marker) staining. EGFR (A) and MET (B) were immunostained with 
EGFR and MET antibody and accumulated at lysosome by treatment with 25mM NH4Cl (lysosomal inhibitor) for 4 
h.  PL16T, immortalized AIS cells. 
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Fig. 18. SFN binds with USP8 and RTKs in lung adenocarcinoma cell lines. 
(A) Endogenous interaction between USP8 and SFN or RTKs such as EGFR and MET was examined by Co-IP in 
A549 cells. As a negative control (NC), the cell lysate and protein A magnetic beads were incubated without 
antibody for 1 h at 4°C. (B) Co-IP using Flag antibody was performed after overexpression of Flag-SFN in PL16T. 
As a negative control, the cell lysate and protein A with IgG antibody were incubated for 1 h at 4°C. The eluted IP 
sample was subjected to Western blot analysis using the indicated antibodies. PL16T, immortalized AIS cells. 
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Fig. 19. Overexpression of SFN enhances stabilization of RTKs in PL16T. 
After transfection with wild type SFN plasmid without any tag, expression of RTKs and downstream factors was 
analyzed by Western blot analysis. EGFR has mainly two phosphorylation sites, Y1045 for degradation pathway and 
Y1068 for proliferation-mediated pathway. MET Y1003 is a phosphorylation site for degradation pathway. β-Actin 
was used as a control to verify equal loading of protein (20 µg). PL16T, immortalized AIS cells. 
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Fig. 20. Knockdown of SFN regulates USP8, RTKs, and the downstream factors in PL16T.  
(A) Transfection efficiency of siSFN was evaluated by SFN expression. Expression of USP8, RTKs, and the 
downstream factors were analyzed by Western blot analysis using cells transfected with siSFN. β-Actin was used as 
a control to verify equal loading of protein (20 µg).  (B) USP8 rescue assay was performed by Western blot analysis 
under co-transfection with siSFN for 24 h and subsequent overexpression of pSFN for 24 h. (C) After siSFN 
transfection for 48 h in A549, the cells treated 10 µM MG132 to inhibit USP8 proteasomal degradation in time 
course. The poly-ubiquitinated USP8 was detected by Western blot analysis. PL16T, immortalized AIS cells. 
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Fig. 21. Knockdown of SFN increases ubiquitinated RTKs in PL16T.  
Expression of ubiquitinated EGFR and MET was assessed by immunoprecipitation after transfection with siSFN 
accompanying the overexpression of HA-ubiquitin. The cells were treated with 25mM NH4Cl (a lysosomal inhibitor) 
for 4 h, leading to accumulation of ubiquitinated EGFR or MET at the lysosome. PL16T, immortalized AIS cells. 
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Fig. 22. Knockdown of SFN induces accumulation of RTKs at lysosome in PL16T.  
After siSFN transfection, ubiquitinated EGFR and MET, which were destined for lysosomal degradation, were 
assessed by immunofluorescence staining employing LAMP1 (lysosomal marker) staining. EGFR and MET were 
immunostained with EGFR and MET antibody and accumulated at lysosome by treatment with 25mM NH4Cl 
(lysosomal inhibitor) for 4 h.  PL16T, immortalized AIS cells. 
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Fig. 23. Knockdown of SFN reduces half-life of RTKs in PL16T.  
(A) The half-life of EGFR and MET was assessed by Western blot analysis after transfection with siSFN. The cells 
were treated with 10 µg/ml cycloheximide (CHX; a protein synthesis inhibitor) to block protein biosynthesis. (B) 
Pulse-chasing assay was performed to determine EGFR half-life after knockdown of SFN. The cells were labeled 
with 35S-Met/Cys (10 µCi/ml) for 30 min and chased in time course 0, 2, 5, and 10 h. The metabolic labeled EGFR 
was scanned β–ray using Typhoon FLA7000 image analyzing system. PL16T, immortalized AIS cells. 
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Fig. 24. USP8 specifically interacts with SFN among 14-3-3 proteins.  
PL16T cells were transfected with various plasmids for 24 h to investigate the interaction between USP8 and 14-3-3 
proteins (HA-epsilon: 14-3-3 epsilon, and Myc-zeta: 14-3-3 zeta). Co-IP was performed using the indicated 
antibodies. Only SFN showed binding with USP8. PL16T, immortalized AIS cells. 
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Fig. 25. USP8 and SFN co-localize in endosomes. 
 Localization of endogenous USP8 and SFN was examined by immunofluorescence staining. EEA1 and LAMP1 
were used as early and late endosome markers, respectively. USP8 and SFN showed co-localization at the early and 
late endosome. 
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Fig. 26. Mutant USP8 impairs binding with SFN and decreases RTKs and their 
downstream factors. 
(A) Mutant USP8 S718C contained a point mutation changing serine to cysteine at amino acid 718, which is one of 
the important phosphorylation residues of the 14-3-3 binding motif (AA715-720, RSYSSP) in USP8. Cells 
transfected with USP8 WT (wild type) or USP8 S718C (mutant) were tested for their interaction with SFN by co-IP. 
p14-3-3 BM (phospho-14-3-3 binding motif) indicates the active form of USP8 (phospho-USP8). (B) After 
transfection with the wild type or two kinds of mutant USP8, expression of RTKs and downstream factors was 
analyzed by Western blot analysis. GFP-USP8 C786S was used as a positive control to inhibit the deubiquitination 
activity of USP8. β-Actin was used as a control to verify equal loading of protein (20 µg). 
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Fig. 27. Mutant SFN impairs binding with USP8 and decreases RTKs expression. 
(A) Mutant SFN contained four multiple point mutations at 49, 56, 129, and 130 residues, which is the important 
residues for recognizing of phospho-target proteins such as RSYSSP for USP8. Cells transfected with SFN WT 
(wild type) or mutant SFN accompanying with USP8 WT were tested for their interaction with Flag by co-IP in 
PL16T. (B) Single point mutant SFN containing a single point mutation at 49, 56, 129 and 130 residues, respectively. 
Cells transfected with each single point mutant SFN was performed co-IP. (C, D) After transfection with the wild 
type or mutant USP8 and SFN, expression of RTKs and downstream factors was analyzed by Western blot analysis. 
β-Actin was used as a control to verify equal loading of protein (20 µg). PL16T, immortalized AIS cells. 
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Fig. 28. SFN-USP8 complex is regulated by Serine/Threonine kinase and phosphatase. 
SFN-USP8 complex was evaluated by co-IP and Western blot analysis. pBM is phospho 14-3-3 binding motif , 
indicating phospho-USP8 and that provides USP8 binding with SFN. (A) A549 cells were treated with 50 µM 
LY294002, an AKT (Serine/Threonine kinase) inhibitor for 1 h. pAKT was used as a positive control for 
Serine/Threonine kinase inhibitor. (B) A549 cells were treated with 200 nM okadaic acid, an PP1 or PP2A 
(Seine/Threonine phosphatase) specific inhibitor for 1 h. pERK was used as a positive control for Serine/Threonine 
phosphatase inhibitor. β-Actin was used as a control to verify equal loading of protein (20 µg). 
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Fig. 29. A model for regulation pathway of RTKs in normal and tumor of lung cells. 
Ligand-bound RTKs are internalized through endocytosis and form early endosomes. Some internalized RTKs are 
subjected to lysosomal degradation, but others undergo recycling back to the plasma membrane via recycling 
endosomes through USP8 activation. In normal cells, ubiquitinated RTKs maintain the balance between the 
recycling and degradation pathways, as well as physiologic regulation of biosynthesis. However, in tumor cells, SFN 
and USP8 show abnormal overexpression and their complex facilitates recycling of RTKs to the plasma membrane 
through deubiquitination of ubiquitinated RTKs. Subsequently, increased stabilization of RTKs on the plasma 
membrane contributes to aberrant cellular proliferation.   
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